PT
Protagenic Therapeutics, Inc.
PTIXW · NASDAQ
$0.02 +0.00% (+$0.00)
Market Cap $30.8K
P/E Ratio -
Div. Yield -
ROE 336.39%
Bulios Fair Price
$0.02
25.0% upside
Current Price
$0.016
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PTIXW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/S -1.23x
PEG N/A
P/E N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
100 /100
Strong Op. margin 26,048.10%
Gross margin 300.00%
FCF margin 18,095.40%
Quality
70 /100
Excellent ROA 415.97%
ROIC 148.76%
Asset turnover -0.01x
Debt
50 /100
Moderate Net debt/EBITDA -0.05x
Current ratio 0.29x
Int. coverage -28.64x
Stability
46 /100
Moderate Profitable years 0
Beta 0.47x
EPS volatility 40.82%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PTIXW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Garo H. Armen
Employees
1
Headquarters
New York City